MA40074A - Composés liant ras multivalents - Google Patents
Composés liant ras multivalentsInfo
- Publication number
- MA40074A MA40074A MA040074A MA40074A MA40074A MA 40074 A MA40074 A MA 40074A MA 040074 A MA040074 A MA 040074A MA 40074 A MA40074 A MA 40074A MA 40074 A MA40074 A MA 40074A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compounds
- multivalent
- binding compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne, entre autres, des composés qui lient sélectivement une protéine ras en deux sites ou davantage et des procédés pour leur synthèse. L'invention concerne également des compositions et des kits contenant les composés, ainsi que des procédés d'utilisation des composés et des compositions pour améliorer ou traiter les effets d'une maladie associée à une signalisation ras modifiée, comme un cancer, chez un sujet et des procédés pour provoquer la mort des cellules cancéreuses. L'invention concerne également des procédés d'identification d'un composé multivalent qui se lie sélectivement à une protéine cible.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462005831P | 2014-05-30 | 2014-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40074A true MA40074A (fr) | 2015-12-03 |
Family
ID=54700076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040074A MA40074A (fr) | 2014-05-30 | 2015-05-29 | Composés liant ras multivalents |
Country Status (5)
Country | Link |
---|---|
US (1) | US9926293B2 (fr) |
EP (1) | EP3148981A4 (fr) |
CA (1) | CA2950581A1 (fr) |
MA (1) | MA40074A (fr) |
WO (1) | WO2015184349A2 (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
KR20180005178A (ko) | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | 치환된 퀴나졸린 화합물 및 이의 사용방법 |
JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Krasの縮合三環系インヒビターおよびその使用の方法 |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3356354A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
EP3356351A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356349A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
EP3356339A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
WO2017070256A2 (fr) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Méthode de criblage d'inhibiteurs de ras |
EA038635B9 (ru) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения |
WO2017100546A1 (fr) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Procédés de préparation de dérivés de quinazoléine |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
WO2017201161A1 (fr) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質の阻害剤 |
CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
WO2018126192A1 (fr) * | 2016-12-30 | 2018-07-05 | Children's Medical Center Corporation | Map2k1 (mek1) utilisée comme cible thérapeutique pour des malformations artérioveineuses et des troubles associés |
WO2018140513A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
WO2018140600A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation |
EP3573964A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
EP3573970A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
HRP20230377T1 (hr) | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
MA52897A (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | Diminution de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaire |
WO2020146613A1 (fr) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
EP4021444A4 (fr) | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
CA3152025A1 (fr) | 2019-09-24 | 2021-04-01 | David BRIERE | Polytherapies |
WO2021127217A1 (fr) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer |
CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
WO2021222138A1 (fr) * | 2020-04-27 | 2021-11-04 | Development Center For Biotechnology | Composés pour la dégradation de la protéine ras mutante |
WO2023150639A2 (fr) * | 2022-02-04 | 2023-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Modulateurs à petites molécules d'enzymes gtpase et leurs utilisations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169788B2 (en) * | 2001-10-30 | 2007-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2007062399A2 (fr) * | 2005-11-23 | 2007-05-31 | The Board Of Regents Of The University Of Texas System | Compose cytotoxique speficique du ras oncogene et ses procedes d’utilisation |
ES2660116T3 (es) * | 2011-08-18 | 2018-03-20 | Biodelivery Sciences International, Inc. | Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina |
EP2836482B1 (fr) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions et méthodes pour le traitement du cancer |
EP2671575A1 (fr) * | 2012-06-04 | 2013-12-11 | Universität Regensburg | Inhibiteurs de RAS |
BR112016011734A2 (pt) * | 2013-11-25 | 2017-08-08 | Novogen ltd | Indóis substituídos e funcionalizados como agentes anti-câncer |
US20170158702A1 (en) * | 2015-12-02 | 2017-06-08 | Kyras Therapeutics, Inc. | Multivalent ras binding compounds |
-
2015
- 2015-05-29 EP EP15798672.0A patent/EP3148981A4/fr not_active Withdrawn
- 2015-05-29 WO PCT/US2015/033318 patent/WO2015184349A2/fr active Application Filing
- 2015-05-29 CA CA2950581A patent/CA2950581A1/fr not_active Abandoned
- 2015-05-29 MA MA040074A patent/MA40074A/fr unknown
-
2016
- 2016-03-22 US US15/077,865 patent/US9926293B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20160229836A1 (en) | 2016-08-11 |
EP3148981A2 (fr) | 2017-04-05 |
EP3148981A4 (fr) | 2017-11-08 |
WO2015184349A2 (fr) | 2015-12-03 |
WO2015184349A3 (fr) | 2016-01-21 |
US9926293B2 (en) | 2018-03-27 |
CA2950581A1 (fr) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40074A (fr) | Composés liant ras multivalents | |
MX2018016344A (es) | Miembros de union lag-3. | |
PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
NZ754051A (en) | Novel antibodies and uses thereof | |
MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
PH12018500156A1 (en) | Antibody constructs for egfrviii and cd3 | |
CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
MY184895A (en) | Antibody constructs for dll3 and cd3 | |
NZ738979A (en) | Pd-1 antibodies | |
JO3714B1 (ar) | تركيبات الجسم المضاد لـ cd70 و cd3 | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
WO2017035430A3 (fr) | Anticorps anti-alk et leurs procédés d'utilisation | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников |